Premium
Improved tolerability of ritonavir derived from pharmacokinetic principles
Author(s) -
Michael Barry
Publication year - 1996
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1996.d01-3339.x
Subject(s) - tolerability , ritonavir , citation , medicine , pharmacokinetics , library science , pharmacology , computer science , human immunodeficiency virus (hiv) , family medicine , antiretroviral therapy , adverse effect , viral load
Ritonavir, an inhibitor of the HIV protease enzyme, is one of the most potent drugs available for the treatment of patients with HIV infection [1]. Preliminary data suggest the administration of ritonavir to patients with advanced disease may result in a significant reduction in mortality [2]. The current recommended dose, 600 mg twice daily, has been demonstrated to produce a viral load reduction of −2.0 log10 ( by RNA PCR) which was sustained at −0.81 log10 by 32 weeks [3]. This was associated with an increase in the CD4 count of 230 cells/mm3 above pretreatment levels. We report our experience with this new anti-HIV agent and 24 12